Literature DB >> 7474276

Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas.

M Weiss1, C L Loprinzi, E T Creagan, R J Dalton, P Novotny, J R O'Fallon.   

Abstract

OBJECTIVE: To determine the effectiveness of follow-up tests for signaling recurrences in patients with intermediate- and high-risk malignant melanomas treated with curative intention.
DESIGN: Retrospective analysis of prospectively collected data.
SETTING: North Central Cancer Treatment Group. PATIENTS: A total of 261 patients with resected local (> or = 1.69 mm) and regional nodal malignant melanomas who were enrolled in a single prospective adjuvant trial were studied. All patients were scheduled to be followed up monthly for 2 months, then every 2 months for the first year, every 4 months the second year, every 6 months the next 3 years, and annually thereafter, with each visit consisting of a history, physical examination, complete blood cell count, blood chemistry panel, and a chest x-ray.
RESULTS: Of the 145 evaluable patients who developed recurrent melanomas, 99 patients (68%) developed symptoms that signaled the diagnosis of recurrent disease. Physical examination of asymptomatic patients led to the diagnosis of recurrent disease in 37 patients (26%). The other nine patients (6%) with recurrent disease had abnormal chest x-rays. Laboratory results were never a sole indicator of recurrent disease.
CONCLUSION: The majority of recurrences following resection of primary melanomas are discovered by history and/or physical examination despite the frequent use of other follow-up tests. The present data indicate that routine blood analyses and chest x-rays have limited value in the postoperative follow-up of patients with resected intermediate- and high-risk melanomas.

Entities:  

Mesh:

Year:  1995        PMID: 7474276

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  16 in total

1.  Costs and benefits of routine follow-up after curative treatment for endometrial cancer.

Authors:  O O Agboola; E Grunfeld; D Coyle; G A Perry
Journal:  CMAJ       Date:  1997-10-01       Impact factor: 8.262

2.  The doctrine of early intervention.

Authors:  K Sweeney; D P Gray; P Evans; R Steele
Journal:  BMJ       Date:  1996-11-02

Review 3.  Follow-up in patients with low-risk cutaneous melanoma: is it worth it?

Authors:  Ulrike Leiter; Thomas Eigentler; Claus Garbe
Journal:  Melanoma Manag       Date:  2014-12-04

4.  Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma.

Authors:  Erin R DeRose; Alexander Pleet; Wei Wang; Virginia J Seery; Mee Young Lee; Sharon Renzi; Ryan J Sullivan; Michael B Atkins
Journal:  Melanoma Res       Date:  2011-08       Impact factor: 3.599

5.  Pulmonary Surveillance Strategies Following Sarcoma Excision Vary Among Orthopedic Oncologists: A Survey of the Musculoskeletal Tumor Society.

Authors:  Zachary Ries; C Parker Gibbs; Mark T Scarborough; Benjamin J Miller
Journal:  Iowa Orthop J       Date:  2016

Review 6.  Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review.

Authors:  Kate D Cromwell; Merrick I Ross; Yan Xing; Jeffrey E Gershenwald; Richard E Royal; Anthony Lucci; Jeffrey E Lee; Janice N Cormier
Journal:  Melanoma Res       Date:  2012-10       Impact factor: 3.599

7.  Prevalence and correlates of skin self-examination behaviors among melanoma survivors: a systematic review.

Authors:  Trishnee Bhurosy; Carolyn J Heckman; Mary Riley
Journal:  Transl Behav Med       Date:  2020-10-12       Impact factor: 3.046

Review 8.  A Global Review of Melanoma Follow-up Guidelines.

Authors:  Shannon C Trotter; Novie Sroa; Richard R Winkelmann; Thomas Olencki; Mark Bechtel
Journal:  J Clin Aesthet Dermatol       Date:  2013-09

9.  Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy.

Authors:  April K S Salama; Nicole de Rosa; Randall P Scheri; Scott K Pruitt; James E Herndon; Jennifer Marcello; Douglas S Tyler; Amy P Abernethy
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

10.  Adjuvant treatment of melanoma.

Authors:  J A Moreno Nogueira; M Valero Arbizu; R Pérez Temprano
Journal:  ISRN Dermatol       Date:  2013-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.